GLP-1 Alcohol Cravings: What the 2026 Evidence Actually Says

Quick first-scroll: find your situation

Do GLP-1s really reduce alcohol cravings?

For semaglutide, yes — with growing randomized evidence. For the rest of the GLP-1 class, the picture is mixed or thin. Two semaglutide RCTs and several large observational studies show reduced craving and reduced drinks per drinking day. The signal does not clearly extend to drinking on more abstinent days. And the strongest direct evidence is in adults with both AUD and obesity — not the general population.

What the science says GLP-1s do change (semaglutide-led)

• Alcohol craving. Measured on the Penn Alcohol Craving Scale, semaglutide cut weekly craving with a statistically significant effect (β = −0.39, P = 0.01) in the JAMA Psychiatry trial (Hendershot et al., 2025).
• Drinks per drinking day. People drink less per session, even when they don't drink less often.
• Heavy drinking days. The 2026 SEMALCO Lancet trial cut heavy drinking days by 41.1 percentage points with semaglutide vs. 26.4 with placebo. Between-group difference: 13.7 percentage points (95% CI −22 to −5.4; P = 0.0015).
• Alcohol-related hospitalizations. A Swedish within-individual cohort of about 227,868 people with AUD found lower alcohol-related hospitalization risk during semaglutide-use periods compared with non-use periods.

What GLP-1s do not clearly change

• Number of drinking vs. abstinent days. In the 2025 JAMA trial, semaglutide did not reduce how many days people drank — it reduced how much they drank on those days (P = 0.89). It's not a sobriety drug.
• Average drinks per calendar day. Statistically not significant in the 2025 trial (P = 0.17).
• Long-term outcomes. No published semaglutide AUD trial has reported follow-up beyond 26 weeks.

What the clinical evidence actually shows: every trial, every effect size

Four randomized human trials with alcohol-related outcomes have been published, plus six large observational studies. Semaglutide has the most data and the cleanest signal.

The GLP-1 alcohol cravings evidence tracker

Source links open in new tabs. Last verified May 7, 2026.

How to read this table

• β is a standardized regression coefficient. Bigger absolute number = bigger effect.
• Cohen's d: 0.2 = small, 0.5 = medium, 0.8 = large.
• HR (hazard ratio) below 1.0 means lower risk on the drug.
• NS = not statistically significant.
• CI = confidence interval. If it crosses 1.0 for HRs (or 0 for differences), the result isn't statistically reliable.

What changes vs. what doesn't (the outcome decomposition)

Why might a GLP-1 reduce alcohol cravings?

Two systems are most discussed: the brain's reward circuit and the gut's absorption pathway. Neither is fully proven in humans. Both have plausible support.

The brain pathway

GLP-1 receptors are present in parts of the brain that handle reward and motivation — especially the ventral tegmental area, the start of the brain's dopamine reward circuit. Animal studies and some human research suggest that activating these receptors dampens the dopamine signal alcohol normally produces, making drinking less rewarding. That's why people on these drugs say things like “alcohol just doesn't hit the same” or “I don't even think about wine anymore.” It's not aversion. It's the brain reward fading.

The gut pathway

GLP-1 medications slow how fast your stomach empties. A 2025 pilot study in Scientific Reports found that people on GLP-1s had a delayed rise in breath alcohol concentration after drinking — meaning the alcohol absorbed more slowly. When alcohol absorbs slower, the buzz comes slower and feels different. Some people feel nauseous. Some feel less drunk per drink. Some just stop sooner.

Why both pathways may matter

A drug that only worked in the brain might not change how alcohol physically feels. A drug that only worked in the gut might not change craving (the thinking-about-drinking part). GLP-1s appear to do both. That helps explain why the signal shows up across craving, drinks-per-drinking-day, and heavy-drinking outcomes — and why the strongest effects come at higher doses given over months, not days.

We can't yet predict who will respond and who won't. The mechanism work tells us why the effect is plausible. It doesn't tell us whether it will happen to you.

How long does it take? And does dose matter?

Trial dose-timing data is fairly clear: effects build with dose. Personal prediction is not. What follows comes straight from the published trials — not a forecast of what any one user will experience.

In the 2025 JAMA Psychiatry trial:

• Weeks 1–4 (semaglutide 0.25 mg/week): Small effects on craving. Almost no change in drinking quantity.
• Weeks 5–8 (0.5 mg/week): Effect sizes hit “large” (Cohen's d > 0.8) for heavy drinking days and drinks per drinking day. Weekly craving reduction reached statistical significance.
• Week 9: Lab alcohol self-administration reduced.

In the 2026 SEMALCO trial, participants titrated up to 2.4 mg/week (the standard Wegovy maintenance dose) over 16 weeks, then stayed on it through week 26. The biggest reductions in heavy drinking days appeared in the second half of the study.

If you've been on a GLP-1 for two weeks and your drinking hasn't budged, that's normal in the trial data. The signal in published research mostly shows up between weeks 5 and 26.

GLP-1 by GLP-1: what the evidence says for each

Semaglutide has the most evidence. Tirzepatide has none specific to alcohol in published RCTs. Older drugs are mixed.

Semaglutide (Ozempic, Wegovy, Wegovy HD, Rybelsus)

The drug with the most data — by a wide margin.

• Two RCTs (Hendershot 2025, Klausen 2026) both showed reductions in drinking outcomes.
• Multiple registry studies (Lähteenvuo, Wang) showed lower AUD hospitalizations and lower AUD diagnoses.
• Survey and Reddit data show consistent self-reported craving reduction.

• Ozempic: semaglutide for type 2 diabetes. Doses 0.25–2.0 mg/week.
• Wegovy: semaglutide for chronic weight management. Standard maintenance dose 2.4 mg/week — the dose used in SEMALCO.
• Wegovy HD: higher-dose semaglutide 7.2 mg/week, FDA-approved March 19, 2026. The 7.2 mg dose has not been tested in a published AUD trial.
• Rybelsus: oral semaglutide for type 2 diabetes.

Tirzepatide (Mounjaro, Zepbound)

Less evidence. Don't assume it works the same. Tirzepatide is a “dual agonist” that hits two receptors (GLP-1 and GIP), not one. Eli Lilly states directly that tirzepatide “has not been evaluated for the treatment of alcohol use disorder, and is not indicated for the treatment of alcohol use disorder” (Lilly Medical, 2026). The Quddos 2023 survey found tirzepatide users self-report reduced drinking similar to semaglutide users — that's self-report, not a controlled trial.

Liraglutide (Saxenda, Victoza)

Some signal in the Lähteenvuo Swedish registry. Older drug, less commonly used today. No dedicated AUD RCT published.

Exenatide (Bydureon, Byetta)

The first GLP-1 ever studied for alcohol use disorder. The EXALT trial (2022) tested it in 127 people with alcohol dependence over 26 weeks. Overall result: no effect. A subgroup analysis found people with BMI ≥ 30 did better — which actually predicted what SEMALCO would later find with semaglutide.

Dulaglutide (Trulicity)

Probst 2023 tested dulaglutide in a smoking cessation trial (255 participants). Among 151 baseline drinkers who completed the 12-week alcohol analysis, alcohol consumption was 29% lower with dulaglutide than placebo (relative effect 0.71; 95% CI 0.52–0.97; P = 0.04). Not commonly used for weight loss.

Orforglipron (Foundayo)

FDA-approved on April 1, 2026 for chronic weight management. It is not currently approved for type 2 diabetes. No published alcohol-specific data exists yet. Don't infer an alcohol-craving effect from mechanism alone.

Compounded GLP-1s

Compounded semaglutide, tirzepatide, and liraglutide are not the same regulatory product as the FDA-approved brand medications. Don't assume equal dosing accuracy, formulation, quality controls, or alcohol-craving effects. On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list.

Anecdotes vs. RCTs: why the numbers don't match

Reddit users describe dramatic effects. RCTs show smaller effects on average. Real-world studies sit in the middle. All three can be true at the same time. The reason has to do with selection bias, dose, and what each study is actually measuring.

What the Reddit study showed (Bremmer & Hendershot, 2024)

This was a peer-reviewed thematic analysis of 1,503 alcohol-related posts and comments from r/Semaglutide, r/Mounjaro, and r/Ozempic between June 2021 and March 2023. Of those coded posts and comments:

• 31.0% described reduced drinking quantity
• 28.5% described loss of interest in alcohol
• 10.8% described initiating abstinence
• 10.4% described reduced craving

Important: those percentages are out of coded posts, not out of all GLP-1 users. People who notice a change are far more likely to post about it than people who don't.

Why the meta-analysis showed smaller RCT effects

The Sinha & Ghosal 2025 systematic review pooled three RCTs available before SEMALCO — combined N = 430. The review found reduction in alcohol consumption: SMD −0.24 (not statistically significant). But the same paper pooled six observational studies (2.74 million people) and found a 36% relative reduction in alcohol-related events (HR 0.64, 95% CI 0.59–0.69).

Why the gap?

1. The RCTs in the meta-analysis used lower doses for shorter time periods. Hendershot maxed out at 9 weeks and 1.0 mg/week. Real-world Wegovy users take 2.4 mg for months or years.
2. The RCTs were small. With 48 to 127 people each, even a real medium-sized effect can fail to reach statistical significance.
3. Then SEMALCO published in May 2026 at the full 2.4 mg dose over 26 weeks — and the result was clearly significant (P = 0.0015). The earlier meta-analysis was done before that trial.

Is any GLP-1 FDA-approved for alcohol use disorder?

No. As of May 7, 2026, no GLP-1 receptor agonist is FDA-approved to treat alcohol use disorder. Off-label prescribing happens. It's not the same as approval.

The three FDA-approved AUD medications

If alcohol is your primary concern, these are the medications a doctor would prescribe based on FDA approval and decades of safety data (NIAAA Medications Development Program):

• Disulfiram (Antabuse) — first FDA-approved in 1951. Causes a severe physical reaction if you drink.
• Naltrexone — oral approved 1994; long-acting injectable (Vivitrol) approved 2006. Reduces craving and the rewarding effects of alcohol.
• Acamprosate (Campral) — FDA-approved 2004. Helps maintain abstinence after stopping.

These work. They're underused. In a 2019 NSDUH analysis, only 1.6% of people with AUD received AUD medications, and only 7.3% received any treatment (NIH News in Health, 2021). That's the actual treatment gap.

What “off-label” really means

A doctor can legally prescribe an FDA-approved drug for a use the FDA didn't review. That's off-label. It's not illegal. It's not unregulated. But it does mean:

• The FDA has not reviewed the drug's safety or effectiveness for that use
• Insurance often won't cover it for that use
• The agency that decides what's worth approving has not weighed the benefits against risks for that condition

The trial pipeline

Several semaglutide AUD trials are registered as of May 7, 2026, including NCT07221214, NCT07218354, NCT06015893, NCT05891587, and NCT07509112. Trial phase, sponsor, and expected completion dates change frequently — re-verify on ClinicalTrials.gov before relying on any specific timeline. No Phase 3 trial — the stage required for FDA approval — has completed for any GLP-1 in AUD.

Can GLP-1s replace naltrexone, acamprosate, or disulfiram?

No. The three FDA-approved AUD medications remain the standard. A GLP-1 may make sense if you separately qualify for one based on a labeled metabolic indication (diabetes, obesity). It should not be positioned as a replacement for AUD-specific care.

Combining a GLP-1 with an approved AUD medication is a prescriber-only conversation. Liver function, kidney function, diabetes medications, psychiatric medications, and withdrawal risk all matter.

Drinking on a GLP-1: what to know

Most GLP-1 prescribing labels don't ban alcohol outright — but they don't bless it either. Slowed stomach emptying, pancreatitis warnings, and possible blood-sugar interactions all matter.

Real risks worth knowing

• Worse nausea, especially during dose increases. Alcohol irritates the stomach. So does titrating up on a GLP-1. Combining them tends to make nausea worse.
• Possible hypoglycemia (low blood sugar) if you also take insulin or a sulfonylurea. Alcohol blocks the liver from releasing glucose. The FDA labels for semaglutide and tirzepatide include hypoglycemia warnings when used with these other diabetes drugs.
• Pancreatitis. GLP-1 prescribing labels include pancreatitis warnings. Heavy alcohol use is itself a major cause of pancreatitis. Those risks need to be discussed together.
• Different alcohol experience. The 2025 Sci Rep pilot study found delayed alcohol absorption on GLP-1s. Some people feel less drunk per drink. Some feel sicker. Some feel both.

Practical guidance to discuss with your doctor

• The days right after a dose increase tend to be when GI symptoms peak. Many users avoid drinking those days.
• If you have diabetes and use insulin or a sulfonylurea, blood sugar testing matters more on drinking days.
• If you've had pancreatitis, gallbladder disease, or heavy drinking, the conversation with your doctor is more involved than a simple “is it OK.”

For who shouldn't take a GLP-1 at all, see our GLP-1 Hard Contraindications guide. For a broader look at GLP-1s and drinking safety, see Can You Drink Alcohol on GLP-1 Medications?

The reader-by-reader decision matrix

Different readers need different next steps. Find your situation.

What this page did NOT find evidence for

To be honest with you, here's what the evidence does NOT support — even though plenty of articles imply it does.

• GLP-1s are not a cure for alcoholism. They are not FDA-approved for AUD. Even the strongest 2026 RCT (108 people, 26 weeks) showed real but partial effects.
• No GLP-1 reliably eliminates alcohol cravings for everyone. In the Reddit thematic analysis, 28.5% of coded posts described loss of interest. That tells us the experience is common in the user population that posts. It does not estimate population prevalence.
• GLP-1s do not reliably make people abstain on more days. The 2025 RCT found no effect on drinking days vs. abstinent days (P = 0.89). They reduce drinking per session, not frequency.
• The pre-SEMALCO RCT meta-analysis showed pooled non-significant effects on consumption. SEMALCO 2026 moved the field, but the broader evidence base across drugs is still developing.
• Tirzepatide is not proven for alcohol cravings. Self-report data suggests similar effects to semaglutide. No RCT confirms it. Lilly states tirzepatide has not been evaluated for AUD.
• Effects after stopping the medication are unknown for semaglutide. No published semaglutide AUD trial has reported follow-up beyond 26 weeks of treatment. EXALT had a 6-month post-discontinuation follow-up for exenatide and didn't show sustained alcohol-outcome differences overall.

You're going to make a decision about your body. You deserve all of it.

How to talk to your doctor about this

The best conversation isn't “can I get Ozempic for drinking?” It's “what's the safest evidence-based plan for my alcohol use, and does a GLP-1 fit my situation?”

Bring data, not just feelings

For 2 weeks before your appointment, track:

A heavy drinking day = 5+ drinks for men, 4+ for women.

A script for the visit

“Since starting [medication], my alcohol cravings are [lower / higher / unchanged / came back]. I drink [X drinks] on [Y days] per week. I [have / haven't] noticed any withdrawal symptoms. Can we discuss whether I meet criteria for alcohol use disorder, what evidence-based AUD treatments would fit me, and how a GLP-1 fits in or doesn't?”

Tell them everything

Be honest about:

• Your real drinking amount (not the polite estimate)
• Any morning drinking
• Any past withdrawal symptoms
• Pancreatitis or gallbladder history
• Insulin or sulfonylurea use
• Pregnancy plans
• Eating disorder history
• Whether you're using compounded GLP-1s

Frequently asked questions

How we built this page

More on GLP-1s from The RX Index

• GLP-1 Hard Contraindications: Who Should Avoid
• Is GLP-1 Safe? 16 Checks Before You Start
• Can You Drink Alcohol on GLP-1 Medications?
• Wegovy Pill vs. Injection: Cost & Results
• Foundayo Side Effects
• Orforglipron vs. Zepbound